{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T19:58:20Z","timestamp":1792439900126,"version":"4.5.0"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,25]],"date-time":"2024-03-25T00:00:00Z","timestamp":1711324800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006545","name":"National Institute on Minority Health and Health Disparities","doi-asserted-by":"publisher","award":["U54MD007582"],"award-info":[{"award-number":["U54MD007582"]}],"id":[{"id":"10.13039\/100006545","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["U54CA233396"],"award-info":[{"award-number":["U54CA233396"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.ejps.2024.106754","type":"journal-article","created":{"date-parts":[[2024,3,28]],"date-time":"2024-03-28T22:57:04Z","timestamp":1711666624000},"page":"106754","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Development of novel pyrimidine nucleoside analogs as potential anticancer agents: Synthesis, characterization, and In-vitro evaluation against pancreatic cancer"],"prefix":"10.1016","volume":"196","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6908-823X","authenticated-orcid":false,"given":"Esther","family":"Frimpong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raviteja","family":"Bulusu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3422-5035","authenticated-orcid":false,"given":"Joy","family":"Okoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andriana","family":"Inkoom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nkafu","family":"Ndemazie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherise","family":"Rogers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Agyare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.ejps.2024.106754_bib0001","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1038\/nrclinonc.2016.119","article-title":"Nanomedicine strategies to overcome the pathophysiological barriers of pancreatic cancer","volume":"13","author":"Adiseshaiah","year":"2016","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.ejps.2024.106754_bib0002","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1007\/s00438-022-01943-w","article-title":"FN1 encoding fibronectin as a pivotal signaling gene for therapeutic intervention against pancreatic cancer","volume":"297","author":"Ashok","year":"2022","journal-title":"Mol. Gene. Genom."},{"issue":"6","key":"10.1016\/j.ejps.2024.106754_bib0003","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1200\/JCO.1997.15.6.2403","article-title":"Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial","volume":"15","author":"Burris 3rd","year":"1997","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.ejps.2024.106754_bib0005","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1007\/s11912-012-0290-4","article-title":"The role of the FOLFIRINOX regimen for advanced pancreatic cancer","volume":"15","author":"Conroy","year":"2013","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.ejps.2024.106754_bib0006","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ejphar.2014.07.041","article-title":"Gemcitabine: metabolism and molecular mechanisms of action, sensitivity and chemoresistance in pancreatic cancer","volume":"741","author":"de Sousa Cavalcante","year":"2014","journal-title":"Eur. J. Pharmacol."},{"issue":"19","key":"10.1016\/j.ejps.2024.106754_bib0004","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejps.2024.106754_bib0007","first-page":"1210","article-title":"5-Fluorouracil: a narrative review on the role of regulatory mechanisms in driving resistance to this chemotherapeutic agent","author":"Ghafouri-Fard","year":"2021","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.ejps.2024.106754_bib0008","doi-asserted-by":"crossref","first-page":"21648","DOI":"10.1038\/srep21648","article-title":"MIA PaCa-2 and PANC-1-pancreas ductal adenocarcinoma cell lines with neuroendocrine differentiation and somatostatin receptors","volume":"6","author":"Gradiz","year":"2016","journal-title":"Sci Rep"},{"issue":"5","key":"10.1016\/j.ejps.2024.106754_bib0010","first-page":"375","article-title":"Multidisciplinary standards of care and recent progress in pancreatic ductal adenocarcinoma","volume":"70","author":"Grossberg","year":"2020","journal-title":"Ca Cancer J. Clin."},{"issue":"11","key":"10.1016\/j.ejps.2024.106754_bib0011","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1093\/annonc\/mdl284","article-title":"Pharmacokinetic and demographic markers of 5-fluorouracil toxicity in 181 patients on adjuvant therapy for colorectal cancer","volume":"17","author":"Gusella","year":"2006","journal-title":"Ann. Oncol."},{"issue":"9","key":"10.1016\/j.ejps.2024.106754_bib0012","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1158\/2159-8290.CD-14-0001","article-title":"Patient-derived xenograft models: an emerging platform for translational cancer research","volume":"4","author":"Hidalgo","year":"2014","journal-title":"Cancer Discov."},{"issue":"3","key":"10.1016\/j.ejps.2024.106754_bib0013","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.jconrel.2004.09.001","article-title":"Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing lipophilic gemcitabine prodrugs","volume":"100","author":"Immordino","year":"2004","journal-title":"J. Control Release"},{"issue":"7","key":"10.1016\/j.ejps.2024.106754_bib0014","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s12094-010-0540-6","article-title":"Patient-derived human tumour tissue xenografts in immunodeficient mice: a systematic review","volume":"12","author":"Jin","year":"2010","journal-title":"Clin. Transl. Oncol."},{"issue":"88","key":"10.1016\/j.ejps.2024.106754_bib0015","first-page":"e51046","article-title":"In-vitro cell migration and invasion assays","author":"Justus","year":"2014","journal-title":"J. Vis. Exp."},{"issue":"2","key":"10.1016\/j.ejps.2024.106754_bib0016","doi-asserted-by":"crossref","first-page":"554","DOI":"10.3390\/pharmaceutics15020554","article-title":"Cannabidiol-Loaded Extracellular Vesicles from Human Umbilical Cord Mesenchymal Stem Cells Alleviate Paclitaxel-Induced Peripheral Neuropathy","volume":"15","author":"Kalvala","year":"2023","journal-title":"Pharmaceutics"},{"issue":"4","key":"10.1016\/j.ejps.2024.106754_bib0017","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1097\/MPA.0000000000000323","article-title":"Pancreatic cancer disparities in African Americans","volume":"44","author":"Khawja","year":"2015","journal-title":"Pancreas"},{"issue":"2","key":"10.1016\/j.ejps.2024.106754_bib0018","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1002\/med.21379","article-title":"Direct activation of bax protein for cancer therapy","volume":"36","author":"Liu","year":"2016","journal-title":"Med. Res. Rev."},{"issue":"5\u20136","key":"10.1016\/j.ejps.2024.106754_bib0019","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1080\/1061186X.2018.1547733","article-title":"Drug delivery to tumours using a novel 5-FU derivative encapsulated into lipid nanocapsules","volume":"27","author":"Lollo","year":"2019","journal-title":"J. Drug Target"},{"issue":"21","key":"10.1016\/j.ejps.2024.106754_bib0020","doi-asserted-by":"crossref","first-page":"3373","DOI":"10.1080\/15384101.2015.1090066","article-title":"p53-mediated control of gene expression via mRNA translation during Endoplasmic Reticulum stress","volume":"14","author":"Lopez","year":"2015","journal-title":"Cell Cycle"},{"issue":"43","key":"10.1016\/j.ejps.2024.106754_bib0021","doi-asserted-by":"crossref","first-page":"4846","DOI":"10.3748\/wjg.v24.i43.4846","article-title":"Pancreatic cancer: a review of clinical diagnosis, epidemiology, treatment and outcomes","volume":"24","author":"McGuigan","year":"2018","journal-title":"World J. Gastroenterol."},{"issue":"3","key":"10.1016\/j.ejps.2024.106754_bib0022","doi-asserted-by":"crossref","first-page":"487","DOI":"10.21037\/jgo.2016.03.03","article-title":"Targeting stromal microenvironment in pancreatic ductal adenocarcinoma: controversies and promises","volume":"7","author":"Mei","year":"2016","journal-title":"J. Gastrointest. Oncol."},{"issue":"2","key":"10.1016\/j.ejps.2024.106754_bib0023","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1136\/gutjnl-2012-303588","article-title":"Current concepts and novel targets in advanced pancreatic cancer","volume":"62","author":"Michl","year":"2013","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.ejps.2024.106754_bib0024","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.canlet.2016.07.022","article-title":"Modifiable and non-modifiable risk factors for pancreatic cancer: a review","volume":"381","author":"Midha","year":"2016","journal-title":"Cancer Lett."},{"issue":"3","key":"10.1016\/j.ejps.2024.106754_bib0025","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.3390\/cancers2031717","article-title":"5-fu metabolism in cancer and orally-administrable 5-fu drugs","volume":"2","author":"Miura","year":"2010","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ejps.2024.106754_bib0026","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1016\/j.biopha.2016.10.096","article-title":"Resveratrol enhances the efficacy of sorafenib mediated apoptosis in human breast cancer MCF7 cells though ROS, cell cycle inhibition, caspase 3 and PARP cleavage","volume":"84","author":"Mondal","year":"2016","journal-title":"Biomed. Pharmacother."},{"issue":"1","key":"10.1016\/j.ejps.2024.106754_bib0027","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1615\/CritRevEukaryotGeneExpr.2013006875","article-title":"Review of poly (ADP-ribose) polymerase (PARP) mechanisms of action and rationale for targeting in cancer and other diseases","volume":"24","author":"Morales","year":"2014","journal-title":"Crit. Rev. Eukaryot. Gene Expr."},{"issue":"1","key":"10.1016\/j.ejps.2024.106754_bib0028","doi-asserted-by":"crossref","first-page":"41962","DOI":"10.1038\/srep41962","article-title":"PARP-1\/PARP-2 double deficiency in mouse T cells results in faulty immune responses and T lymphomas","volume":"7","author":"Navarro","year":"2017","journal-title":"Sci. Rep."},{"issue":"19","key":"10.1016\/j.ejps.2024.106754_bib0029","doi-asserted-by":"crossref","first-page":"31726","DOI":"10.18632\/oncotarget.15956","article-title":"Polyisoprenylated cysteinyl amide inhibitors disrupt actin cytoskeleton organization, induce cell rounding and block migration of non-small cell lung cancer","volume":"8","author":"Ntantie","year":"2017","journal-title":"Oncotarget"},{"issue":"8","key":"10.1016\/j.ejps.2024.106754_bib0030","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1039\/c0nr00132e","article-title":"Liposomal squalenoyl-gemcitabine: formulation, characterization and anticancer activity evaluation","volume":"2","author":"Pili","year":"2010","journal-title":"Nanoscale"},{"issue":"3","key":"10.1016\/j.ejps.2024.106754_bib0031","first-page":"201","article-title":"Theoretical Raman and IR spectra of tegafur and comparison of molecular electrostatic potential surfaces, polarizability and hyerpolarizability of tegafur with 5-fluoro-uracil by density functional theory","volume":"1","author":"Prasad","year":"2010","journal-title":"J. At. Mol. Sci"},{"issue":"8","key":"10.1016\/j.ejps.2024.106754_bib0032","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/nrd.2018.46","article-title":"The expanding role of prodrugs in contemporary drug design and development","volume":"17","author":"Rautio","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"issue":"1","key":"10.1016\/j.ejps.2024.106754_bib0033","first-page":"17","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"Ca Cancer J. Clin."},{"issue":"1","key":"10.1016\/j.ejps.2024.106754_bib0034","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.cgh.2019.05.059","article-title":"Racial disparities and trends in pancreatic cancer incidence and mortality in the United States","volume":"18","author":"Tavakkoli","year":"2020","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"10","key":"10.1016\/j.ejps.2024.106754_bib0035","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1007\/s00595-020-02028-0","article-title":"Pancreatic cancer treatment: better, but a long way to go","volume":"50","author":"Torphy","year":"2020","journal-title":"Surg. Today"},{"issue":"1","key":"10.1016\/j.ejps.2024.106754_bib0036","doi-asserted-by":"crossref","first-page":"eaau7314","DOI":"10.1126\/sciadv.aau7314","article-title":"Improving the metabolic fidelity of cancer models with a physiological cell culture medium","volume":"5","author":"Vande Voorde","year":"2019","journal-title":"Sci. Adv."},{"key":"10.1016\/j.ejps.2024.106754_bib0037","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2019.107447","article-title":"5-fluorouracil and other fluoropyrimidines in colorectal cancer: past, present and future","volume":"206","author":"Vodenkova","year":"2020","journal-title":"Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.ejps.2024.106754_bib0038","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.clinthera.2005.01.005","article-title":"Capecitabine: a review","volume":"27","author":"Walko","year":"2005","journal-title":"Clin. Ther."},{"key":"10.1016\/j.ejps.2024.106754_bib0039","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/2646148","article-title":"Epithelial-mesenchymal transition in pancreatic cancer: a review","author":"Wang","year":"2017","journal-title":"Biomed. Res. Int."},{"issue":"42","key":"10.1016\/j.ejps.2024.106754_bib0040","doi-asserted-by":"crossref","first-page":"15682","DOI":"10.3748\/wjg.v20.i42.15682","article-title":"Recent studies of 5-fluorouracil resistance in pancreatic cancer","volume":"20","author":"Wang","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.ejps.2024.106754_bib0041","series-title":"Chemo Fog: Cancer Chemotherapy-Related Cognitive Impairment","first-page":"157","article-title":"Effects of 5-FU","author":"Wigmore","year":"2010"},{"issue":"2","key":"10.1016\/j.ejps.2024.106754_bib0042","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1053\/j.gastro.2022.03.056","article-title":"Pancreatic cancer: pathogenesis, screening, diagnosis, and treatment","volume":"163","author":"Wood","year":"2022","journal-title":"Gastroenterology"},{"issue":"10","key":"10.1016\/j.ejps.2024.106754_bib0043","doi-asserted-by":"crossref","first-page":"3101","DOI":"10.1016\/j.bmcl.2013.03.003","article-title":"Synthesis, characterization and anti-tumor activity of novel thymoquinone analogs against pancreatic cancer","volume":"23","author":"Yusufi","year":"2013","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"6","key":"10.1016\/j.ejps.2024.106754_bib0044","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1021\/acs.oprd.7b00103","article-title":"Synthesis of Tegafur by the alkylation of 5-fluorouracil under the Lewis acid and metal salt-free conditions","volume":"21","author":"Zasada","year":"2017","journal-title":"Org. Process Res. Dev."},{"issue":"8","key":"10.1016\/j.ejps.2024.106754_bib0045","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.3390\/molecules13081551","article-title":"5-Fluorouracil: mechanisms of resistance and reversal strategies","volume":"13","author":"Zhang","year":"2008","journal-title":"Molecules"}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098724000654?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098724000654?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T03:57:10Z","timestamp":1778558230000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098724000654"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":44,"alternative-id":["S0928098724000654"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2024.106754","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of novel pyrimidine nucleoside analogs as potential anticancer agents: Synthesis, characterization, and In-vitro evaluation against pancreatic cancer","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2024.106754","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"106754"}}